Table 1

Patient demographic characteristics at entry. (P-values are from t-tests comparing those who took each drug to those who did not.)

All Subjects

Subjects with follow up

Exposed to ZDV*

Exposed to ddI†


N

33

23

19

7

Age in years: Mean (Range)

35.3 (23 – 51)

35.5 (23 – 51)

36.2 (23 – 51) (p = .27)

35.4 (25 – 51) (p = .97)

Male, N (%)

31 (94%)

21 (91%)

18 (95%) (p = .20)

6 (86%) (p = .53)

Race, N (%)

White

Black

Hispanic

Asian

24 (73%)

3 (9%)

1 (3%)

5 (15%)

16(70%)

2 (9%)

1 (4%)

4 (17%)

14 (74%)

1 (5%)

0 (0%)

4 (21%) (p = .062)

6 (86%)

0 (0%)

1 (14%)

0 (0%) (p = .15)

CD4+ T-cells/ul Mean (Range)

483 (213 – 1130)

481 (213 – 960)

472 (213 – 960) (p = .64)

714 (444 – 960) (p < .0001)

Plasma HIV RNA‡ 1000 copies per/ml Mean (Range)

102 (0.1 – 670) (N = 31)

75 (0.1 – 505) (N = 22)

87 (0.1 – 505) (p = .69)

2.8 (0.1 – 8.0) (p = .0006)

Low Frequency PTA§in dB Mean (Range)

11 (0 – 40) (N = 32)

12 (0 – 40)

14 (1 – 40) (p = .41)

16 (0.5 – 40) (p = .40)

High Frequency PTA in dB Mean (Range)

20 (0.8 – 51) (N = 32)

22 (1.7 – 51)

22 (2 – 51) (p = .98)

23 (3 – 50) (p = .64)


*ZDV = zidovudine, †ddI = didanosine, ‡RNA = ribonucleic acid, §PTA = pure tone average

Schouten et al. BMC Infectious Diseases 2006 6:28   doi:10.1186/1471-2334-6-28

Open Data